EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Major Depressive Disorder Medication Use Strategies and Analyses

Huimin Song

International Journal of Biology and Life Sciences · 15.11.2026 · 17 (2) · 102-107

DOI: 10.54097/jpnk8c69 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biology and Life Sciences, online erschienen am 15.11.2026. Verfasst von Huimin Song. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) is a pressing mental health problem globally. Under the contemporary era, significant progress has been achieved in understanding the pathogenic mechanisms of MDD. Pharmacotherapy, especially SSRIs, works as the most frequent option in MDD treatment. To identify a molecule with prompt effectiveness and minimal adverse effects is the overarching objective, but the mechanisms underlying the therapeutic effects in the MDD treatment remain nuanced and are not completely revealed. This literature review describes mechanisms, clinical trials conducted, therapeutic benefits along with adverse effects discovered of several key antidepressants, and aims to provide insights into the future antidepressant discovery, development and application. SSRIs together with SNRIs have acute effects on the monoaminergic system, but their strength is subject to limitations imposed by delayed or inadequate therapeutic efficacy, suboptimal remission outcomes, and adverse reactions. Consequently, novel and more efficacious antidepressant therapeutic agents are identified and developed. The review covers the recent clinical findings of a few promising antidepressants, and found that rapid-acting, oral administration, and substantial benefits in both remission and response are optimal features for antidepressants. Taken together, further explorations into both the pharmacological and pathophysiological mechanisms remain necessary. Future studies regarding the assessments of prolonged therapeutic benefits, safety profiles, recognitions of novel biomarkers among MDD patients especially with substance use disorders and/or treatment-resistant depression are also essential.

Zitieren

APA

Song, H. (2026). Major Depressive Disorder Medication Use Strategies and Analyses. International Journal of Biology and Life Sciences, 17(2), 102-107. https://doi.org/10.54097/jpnk8c69

Vancouver

Song H. Major Depressive Disorder Medication Use Strategies and Analyses. International Journal of Biology and Life Sciences. 2026;17(2):102-107. doi:10.54097/jpnk8c69

BibTeX
@article{Song2026,
  author = {Song, Huimin},
  title = {Major Depressive Disorder Medication Use Strategies and Analyses},
  journal = {International Journal of Biology and Life Sciences},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {102--107},
  doi = {10.54097/jpnk8c69}
}
Kostenlos starten →